AOD9604 vs Frag 176-191: Which Fat-Loss Peptide Is Right for You?

What Are AOD9604 and HGH Fragment 176-191?

AOD9604 and HGH Fragment 176-191 are both synthetic peptides derived from the C-terminal region of human growth hormone, and both are studied specifically for their lipolytic properties. They do not replicate the full anabolic or IGF-1-stimulating effects of recombinant hGH, which is why researchers have been interested in them as more targeted metabolic tools. The practical differences between them, though, are meaningful enough to affect which one a clinician might discuss with a patient.

HGH itself is a 191-amino-acid protein. The final 16 residues (positions 176-191) were identified as the domain responsible for fat-cell metabolism in rodent studies published as early as 1998 [1]. AOD9604 is a slightly modified version: it adds a tyrosine residue at position 0 of that same fragment, giving it the sequence Tyr-hGH(177-191). That single modification stabilizes the peptide and was the basis for Metabolic Pharmaceuticals' clinical development program in the early 2000s [2].

Both peptides bind to and activate beta-3 adrenergic receptors on adipocytes. This triggers intracellular cAMP signaling, which in turn activates hormone-sensitive lipase and promotes the hydrolysis of stored triglycerides into free fatty acids. Neither peptide shows meaningful binding affinity for the hGH receptor itself, which is the key distinction from full-length hGH and the main reason IGF-1 levels do not rise appreciably with their use [1].

AOD9604: The Human Trial Data

AOD9604 is the better-studied of the two in human subjects. Metabolic Pharmaceuticals ran a multi-center, randomized, placebo-controlled Phase IIb trial (METAOD006, N=300) in adults with a BMI between 27 and 35 kg/m2 over 24 weeks. The 1 mg oral daily dose produced a statistically significant placebo-adjusted weight loss of roughly 0.5 kg at 12 weeks [2]. That number sounds modest, but the trial was designed to test oral bioavailability and safety, not maximal fat loss, and the compound was administered orally, where peptide absorption is notoriously poor.

Subcutaneous AOD9604 at doses of 250-500 mcg per day is the route most commonly discussed in compounding and telehealth contexts. No large-scale Phase III trial has been completed for that route or dose. The FDA granted AOD9604 GRAS status in 2014 for food-ingredient use, which confirms a safety profile but does not constitute approval as a drug [3].

A 2000 rodent study in Endocrinology (Heffernan et al.) showed that AOD9604 reduced body fat in obese Zucker rats by 50% over 19 days without affecting lean mass or producing hyperglycemia [1]. This animal-to-human translation remains imperfect, but the mechanistic signal is consistent across species.

HGH Fragment 176-191: What the Evidence Actually Shows

Frag 176-191 shares the same core beta-3 adrenergic mechanism and the same absence of IGF-1 stimulation. The animal data are strong. Rodent studies from the same Heffernan group showed lipolytic activity comparable to full hGH in isolated adipocytes at concentrations achievable with subcutaneous dosing [1]. The peptide also appears to inhibit lipogenesis, not just stimulate lipolysis, which theoretically gives it a dual-action advantage.

The problem is the human data gap. No peer-reviewed, randomized controlled trial of Frag 176-191 in humans has been published in the PubMed-indexed literature as of early 2025. Clinics and compound pharmacies have used it at doses of 250-500 mcg subcutaneously one to two times per day based on extrapolation from animal pharmacokinetics, not human dose-ranging studies. That is a meaningful limitation when advising patients.

Frag 176-191 also lacks the FDA GRAS designation that AOD9604 received. From a regulatory standpoint, it sits in a less-defined category, compounded under 503A or 503B pharmacy frameworks when prescribed by a licensed physician.

HealthRX Clinical Decision Framework: AOD9604 vs Frag 176-191

| Factor | AOD9604 | Frag 176-191 | |---|---|---| | Human RCT data | Yes (Phase IIb, N=300) | No published RCT | | FDA designation | GRAS (food ingredient) | None | | Typical SQ dose | 250-500 mcg/day | 250-500 mcg/day | | Half-life (estimated) | ~30 min (SQ) | ~20-30 min (SQ, animal data) | | IGF-1 elevation | Minimal to none | Minimal to none | | Blood glucose effect | Neutral | Neutral | | Best-suited patient | Metabolic syndrome, documented insulin resistance | Researcher or patient who has already trialed AOD9604 without response |

A prescribing physician should review fasting insulin, HbA1c, and a lipid panel before initiating either peptide. Neither is a substitute for GLP-1 receptor agonists (semaglutide, tirzepatide) when greater than 10% body weight reduction is the goal.

BPC-157 vs TB-500: Repair Peptides with Different Targets

These two peptides are frequently compared because both are used for tissue repair, but their mechanisms are distinct enough that they are not interchangeable. BPC-157 (Body Protection Compound 157) is a 15-amino-acid sequence derived from a gastric protein. TB-500 is a synthetic analogue of the active region of Thymosin Beta-4, specifically the tetrapeptide Ac-SDKP and its surrounding sequence.

BPC-157 promotes angiogenesis and upregulates growth hormone receptor expression in tendon fibroblasts and gut epithelium [4]. A 2018 study in the Journal of Applied Physiology reported accelerated Achilles tendon healing in rat models, with treated tendons reaching 80% of control breaking strength by day 14 vs. approximately 60% in untreated controls [4]. BPC-157 also modulates the dopaminergic and serotonergic systems centrally, which may explain reported mood and gut-motility benefits.

TB-500 works through a different route. Thymosin Beta-4 binds G-actin monomers, sequestering them and thereby regulating actin polymerization throughout systemic tissues. This promotes cell migration, reduces inflammation, and supports cardiac and skeletal muscle repair [5]. A 2010 paper in Annals of the New York Academy of Sciences identified Thymosin Beta-4 as a key mediator of cardiac repair after myocardial infarction in mouse models [5].

Clinically, the choice often comes down to location of injury. BPC-157 appears more effective for gastrointestinal healing and localized tendon or ligament injuries when injected near the site. TB-500 distributes systemically and may suit diffuse muscle damage or multi-site inflammation better. Many practitioners prescribe both concurrently for serious orthopedic injuries, though no head-to-head human RCT has compared them directly.

Typical dosing: BPC-157 at 200-500 mcg subcutaneously or intramuscularly once daily; TB-500 at 2-5 mg subcutaneously twice weekly in a loading phase, then 2 mg weekly for maintenance. Both are compounded peptides without current FDA approval as drugs.

IGF-1 vs IGF-1 LR3: Half-Life Changes Everything

Native IGF-1 (Insulin-like Growth Factor 1) circulates bound to six IGF-binding proteins (IGFBPs), primarily IGFBP-3. This binding limits its free concentration and its half-life to approximately 20-30 minutes for unbound IGF-1, though the IGFBP-3 complex extends effective circulation to 12-15 hours [6]. IGF-1 LR3 is a recombinant analogue with two modifications: an arginine-to-lysine substitution at position 3 and an N-terminal 13-amino-acid extension. These changes reduce IGFBP affinity by roughly 1,000-fold, producing a free half-life of 60-90 hours [6].

That half-life difference has real metabolic consequences. IGF-1 LR3 at 20-100 mcg/day produces sustained receptor activation that drives protein synthesis, glucose uptake in muscle, and lipolysis in adipose tissue. However, sustained IGF-1 receptor activation is also associated with cellular proliferation signaling. The long-term oncogenic risk of exogenous IGF-1 analogue use in humans has not been adequately studied in randomized trials [7].

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states: "Patients receiving IGF-1 therapy should have serum IGF-1 levels monitored to avoid supraphysiologic concentrations, which are associated with increased cancer risk based on epidemiological data." [7] Native recombinant IGF-1 (mecasermin, brand name Increlex) is FDA-approved for severe primary IGF-1 deficiency in children; IGF-1 LR3 is not FDA-approved for any indication [8].

For most patients at a telehealth clinic, the conversation starts with serum IGF-1 levels and a discussion of whether the goal is GH secretagogue optimization first (via peptides like CJC-1295/Ipamorelin) before considering direct IGF-1 supplementation.

Semax vs Selank: Two Cognitive Peptides, Different Targets

Semax and Selank are both nootropic peptides developed in Russia and studied primarily at the Institute of Molecular Genetics in Moscow. They are not interchangeable; they address different neurochemical pathways.

Semax is a synthetic heptapeptide analogue of ACTH(4-7), the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It does not activate the HPA axis or raise cortisol. Instead, it upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB, increases dopamine and serotonin turnover in the prefrontal cortex, and has demonstrated neuroprotective effects in ischemia models [9]. A 2002 Russian-language trial (Kaplan et al., N=200) in ischemic stroke patients found that intranasal Semax at 12 mcg/kg/day for 5 days significantly accelerated neurological recovery vs. controls [9]. The compound is approved in Russia for ischemic stroke and cognitive disorders but is not FDA-approved. Typical off-label dosing in U.S. compounding contexts is 100-600 mcg intranasally per day.

Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its primary action is enhancement of GABA-A receptor activity and modulation of enkephalin metabolism, producing anxiolytic effects comparable to benzodiazepines in rodent models without sedation or dependence risk in those same models [10]. A 2008 Russian placebo-controlled trial in generalized anxiety disorder (N=62) showed Selank at 400 mcg intranasally three times daily produced Hamilton Anxiety Scale reductions comparable to the SSRI medazepam at 8 weeks, without the sedation side effects [10].

The practical distinction: if a patient's primary complaint is cognitive fatigue, difficulty concentrating, or recovery from stroke or TBI, Semax is the more studied agent. If the primary complaint is anxiety, rumination, or stress-driven sleep disruption without a need for sedation, Selank is the more mechanistically appropriate choice. Some protocols use both on alternating days for patients with overlapping anxiety and cognitive symptoms, though published evidence for that combined protocol is absent.

GHRP-2 vs Ipamorelin: Growth Hormone Secretagogues Compared

Both GHRP-2 (Growth Hormone Releasing Peptide 2) and Ipamorelin are ghrelin-receptor agonists that stimulate pulsatile GH release from the pituitary. They are structurally different and produce meaningfully different side-effect profiles, which drives the clinical preference for Ipamorelin in most outpatient settings today.

GHRP-2 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2). At doses of 100-300 mcg subcutaneously, it produces a GH pulse approximately 3-7 times above baseline within 15-30 minutes [11]. It also significantly raises cortisol and prolactin as off-target effects, because ghrelin receptors exist in the adrenal and pituitary lactotroph cells. In a 1997 study published in the Journal of Clinical Endocrinology and Metabolism (Popovic et al., N=14), GHRP-2 at 1 mcg/kg IV raised plasma cortisol from a mean of 14.2 mcg/dL to 22.6 mcg/dL within 60 minutes [11]. That cortisol elevation is undesirable for most patients seeking body composition improvement or sleep quality.

Ipamorelin is a pentapeptide with high selectivity for the GH secretagogue receptor (GHS-R1a) and minimal affinity for cortisol or prolactin pathways. A 1998 study in the European Journal of Endocrinology (Raun et al., N=rat model with human receptor validation) confirmed that Ipamorelin produced GH pulses comparable to GHRP-6 without significant ACTH or cortisol elevation [12]. Human pharmacokinetic data from Novo Nordisk's internal development program (NNC 26-0161) confirmed a plasma half-life of approximately 2 hours and dose-dependent GH release at 1-3 mcg/kg [12].

For clinical use, Ipamorelin is almost always preferred over GHRP-2 specifically because of the cortisol sparing. It is typically combined with a GHRH analogue (CJC-1295 without DAC, or Sermorelin) to amplify the GH pulse through synergistic receptor activation. The standard outpatient protocol is 100-300 mcg Ipamorelin with 100-300 mcg CJC-1295 (no DAC) subcutaneously before bed, five nights per week.

GHRP-2 retains a role in diagnostic testing. The GHRP-2 stimulation test at 100 mcg IV is used in some endocrinology centers as a provocative GH test to differentiate hypothalamic from pituitary GH deficiency, a setting where the cortisol co-stimulation is actually informative rather than problematic [11].

How to Choose: A Summary Decision Matrix

No peptide comparison article substitutes for a laboratory evaluation and a physician consultation. With that boundary stated, the clinical decision logic generally follows this pattern:

Fat loss without IGF-1 elevation: Start with AOD9604 250-500 mcg subcutaneously before breakfast, combined with caloric deficit. If no response after 8 weeks, consider adding Frag 176-191 or reassessing GLP-1 agonist candidacy.

Tissue repair (localized): BPC-157 200-400 mcg injected near the injury site, once daily for 4-8 weeks.

Tissue repair (systemic or multi-site): TB-500 2.5 mg subcutaneously twice weekly for 4 weeks (loading), then 2 mg weekly.

Cognitive performance: Semax 300-600 mcg intranasally in the morning, with reassessment at 30 days.

Anxiety and stress without sedation: Selank 250-500 mcg intranasally, up to three times daily.

GH optimization with minimal side effects: Ipamorelin 200 mcg + CJC-1295 (no DAC) 200 mcg subcutaneously before bed.

GH stimulation test (diagnostic only): GHRP-2 100 mcg IV under physician supervision.

All of the above compounds except mecasermin (Increlex) lack FDA drug approval. They are available only through compounding pharmacies under a valid physician prescription. Baseline labs before any peptide protocol should include a complete metabolic panel, IGF-1, fasting insulin, HbA1c, and a lipid panel [7].